- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Lambert-Eaton myasthenic syndrome
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1494KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 280KB)
Amifampridine – November 2021
Amifampridine: Tablet 10 mg; Ruzurgi®
Last updated
18 March 2022